日本ケミファの株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2021/01/07 | 2,225 | 2,302 | 2,225 | 2,241 | +18 | +0.8% | 3,700 |
2021/01/06 | 2,210 | 2,231 | 2,202 | 2,223 | +13 | +0.6% | 2,600 |
2021/01/05 | 2,238 | 2,238 | 2,206 | 2,210 | -28 | -1.3% | 2,800 |
2021/01/04 | 2,254 | 2,254 | 2,238 | 2,238 | +38 | +1.7% | 1,300 |
2020/12/30 | 2,265 | 2,265 | 2,200 | 2,200 | -27 | -1.2% | 2,600 |
2020/12/29 | 2,224 | 2,227 | 2,224 | 2,227 | +16 | +0.7% | 700 |
2020/12/28 | 2,248 | 2,248 | 2,201 | 2,211 | -37 | -1.6% | 4,300 |
2020/12/25 | 2,265 | 2,265 | 2,234 | 2,248 | -17 | -0.8% | 3,700 |
2020/12/24 | 2,313 | 2,314 | 2,265 | 2,265 | -35 | -1.5% | 4,400 |
2020/12/23 | 2,313 | 2,314 | 2,300 | 2,300 | -13 | -0.6% | 4,600 |
2020/12/22 | 2,331 | 2,331 | 2,313 | 2,313 | -18 | -0.8% | 2,100 |
2020/12/21 | 2,331 | 2,335 | 2,313 | 2,331 | ±0 | ±0% | 3,100 |
2020/12/18 | 2,334 | 2,346 | 2,331 | 2,331 | -11 | -0.5% | 1,800 |
2020/12/17 | 2,339 | 2,361 | 2,332 | 2,342 | -9 | -0.4% | 4,700 |
2020/12/16 | 2,379 | 2,428 | 2,351 | 2,351 | -41 | -1.7% | 4,200 |
2020/12/15 | 2,351 | 2,424 | 2,351 | 2,392 | -50 | -2% | 2,300 |
2020/12/14 | 2,360 | 2,442 | 2,337 | 2,442 | +83 | +3.5% | 4,800 |
2020/12/11 | 2,380 | 2,380 | 2,330 | 2,359 | +29 | +1.2% | 6,200 |
2020/12/10 | 2,369 | 2,370 | 2,330 | 2,330 | -20 | -0.9% | 3,000 |
2020/12/09 | 2,372 | 2,372 | 2,350 | 2,350 | -22 | -0.9% | 2,900 |
2020/12/08 | 2,379 | 2,379 | 2,356 | 2,372 | +4 | +0.2% | 1,600 |
2020/12/07 | 2,435 | 2,447 | 2,367 | 2,368 | -67 | -2.8% | 4,600 |
2020/12/04 | 2,475 | 2,481 | 2,427 | 2,435 | -43 | -1.7% | 5,600 |
2020/12/03 | 2,474 | 2,494 | 2,474 | 2,478 | +6 | +0.2% | 1,700 |
2020/12/02 | 2,488 | 2,494 | 2,472 | 2,472 | +2 | +0.1% | 3,700 |
2020/12/01 | 2,470 | 2,494 | 2,470 | 2,470 | ±0 | ±0% | 1,500 |
2020/11/30 | 2,500 | 2,500 | 2,470 | 2,470 | -28 | -1.1% | 7,900 |
2020/11/27 | 2,471 | 2,500 | 2,447 | 2,498 | +87 | +3.6% | 3,900 |
2020/11/26 | 2,489 | 2,490 | 2,410 | 2,411 | -60 | -2.4% | 3,800 |
2020/11/25 | 2,441 | 2,493 | 2,441 | 2,471 | +2 | +0.1% | 3,600 |
2020/11/24 | 2,499 | 2,499 | 2,469 | 2,469 | +9 | +0.4% | 2,800 |
2020/11/20 | 2,485 | 2,485 | 2,456 | 2,460 | -25 | -1% | 600 |
2020/11/19 | 2,426 | 2,486 | 2,426 | 2,485 | +11 | +0.4% | 2,900 |
2020/11/18 | 2,510 | 2,510 | 2,446 | 2,474 | -36 | -1.4% | 3,100 |
2020/11/17 | 2,508 | 2,525 | 2,508 | 2,510 | -27 | -1.1% | 2,000 |
2020/11/16 | 2,539 | 2,539 | 2,509 | 2,537 | +13 | +0.5% | 2,500 |
2020/11/13 | 2,537 | 2,537 | 2,439 | 2,524 | +5 | +0.2% | 1,300 |
2020/11/12 | 2,507 | 2,525 | 2,499 | 2,519 | -17 | -0.7% | 2,500 |
2020/11/11 | 2,548 | 2,548 | 2,498 | 2,536 | -1 | ±0% | 2,700 |
2020/11/10 | 2,593 | 2,593 | 2,446 | 2,537 | +83 | +3.4% | 2,900 |
2020/11/09 | 2,440 | 2,472 | 2,440 | 2,454 | -5 | -0.2% | 1,400 |
2020/11/06 | 2,448 | 2,459 | 2,448 | 2,459 | -37 | -1.5% | 1,000 |
2020/11/05 | 2,466 | 2,535 | 2,466 | 2,496 | +11 | +0.4% | 2,400 |
2020/11/04 | 2,478 | 2,492 | 2,465 | 2,485 | +10 | +0.4% | 1,700 |
2020/11/02 | 2,550 | 2,556 | 2,475 | 2,475 | -75 | -2.9% | 1,100 |
2020/10/30 | 2,598 | 2,598 | 2,550 | 2,550 | +52 | +2.1% | 600 |
2020/10/29 | 2,508 | 2,528 | 2,498 | 2,498 | -60 | -2.3% | 2,200 |
2020/10/28 | 2,609 | 2,609 | 2,539 | 2,558 | -81 | -3.1% | 1,300 |
2020/10/27 | 2,558 | 2,639 | 2,557 | 2,639 | +31 | +1.2% | 2,100 |
2020/10/26 | 2,599 | 2,608 | 2,593 | 2,608 | +23 | +0.9% | 1,600 |
951~
1000
件表示中 / 3586件
類似銘柄と比較する
現在ご覧いただいている「日ケミファ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
日ケミファ | 151,100円 | +2.5% | - | 3.31% | 90.86倍 | 0.29倍 |
|
中堅後発薬メーカー。長期収載品の主力は痛風薬ウラリット。新薬開発、検査薬事業を中期強化 |
ティムス | 20,500円 | - | - | 0.00% | - | 2.78倍 |
|
東京農工大発創薬ベンチャー。黒カビ由来の急性期脳梗塞薬候補品を香港拠点ジーシンに導出 |
ノイルイミューン | 17,300円 | -97.8% | - | 0.00% | - | 1.50倍 |
|
独自技術用いたCAR-T細胞免疫療法で抗がん剤を複数開発中。中外製薬とライセンス契約 |
カルナバイオ | 31,000円 | -43.1% | - | 0.00% | - | 1.84倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
VIS | 89,000円 | +87.8% | +265.7% | 0.00% | 53.45倍 | 2.45倍 |
|
mRNA標的低分子創薬技術を製薬会社に提供。共同創薬研究などによる契約金収入が柱 |
市場注目の銘柄
チャート関連のコラム